DNA Earnings Prediction
The chart below shows how DNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DNA sees a +1.00% change in stock price 10 days leading up to the earnings, and a -9.74% change 10 days following the report. On the earnings day itself, the stock moves by -1.62%. This data can give you a slight idea of what to expect for the next quarter's release.
DNA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
89.05M
60.65%
58.43%
Gross Margin
86.52%
-1.13%
14.46%
Operating Margin
-59.58%
-79.58%
-78.19%
Net Margin
-63.34%
-88.41%
-83.61%
EPS
-1.08
-575.00%
-74.47%
No Data Available
DNA Earnings Analysis
Ginkgo Bioworks Holdings, Inc. Corporation (DNA.N) Earnings Conference Call
Positive
Non-Cash Revenue Release: Ginkgo reported $45 million in non-cash revenue from a release of deferred revenue related to a customer agreement with Motif FoodWorks, one of their platform ventures.
Cell Engineering Revenue Growth: The cell engineering revenue was $30 million in the quarter, supported a total of 136 active programs across 81 customers on the cell engineering platform, representing a 17% increase in active programs year-over-year.
Technical Milestone Achievement: Ginkgo achieved a $9 million technical milestone with Merck, indicating Ginkgo delivering R&D solutions to blue-chip customers in biopharma.
Strong Cash Position: Ginkgo ended the quarter with $616 million in cash and no bank debt, having already exceeded their cost-cutting target for 2024.
Cost Reduction Strategy: The company expects to see $100 million of costs taken out on an annualized run rate basis this year with an additional $100 million coming out by mid-2025.
Negative
Cell Engineering Revenue Decline: Ginkgo reported a 20% decline in cell engineering revenue compared to Q3 2023, totaling $30 million this quarter.
Non-Cash Revenue Recognition: The company recognized $45 million in non-cash revenue from a deferred revenue release, indicating reliance on one-time revenue sources.
Adjusted EBITDA Decline: Adjusted EBITDA was negative $20 million, a significant drop from negative $84 million in Q3 2023, highlighting ongoing financial struggles.
G&A Expense Reduction: G&A expenses decreased from $49 million in Q3 2023 to $42 million in Q3 2024, reflecting cost-cutting measures but also potential impacts on operational capacity.
Cash Burn Reduction Expectations: The company expects to see a significant decrease in cash burn in Q4, but Q3 cash burn was impacted by non-recurring items totaling approximately $23 million.
DNA FAQs
How does DNA typically perform around its earnings report dates?
Is Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DNA Earning Call Sentiment
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
DNA.N
-7.8%Positive
The earnings call reveals challenges such as a 20% decline in cell engineering revenue and high cash burn due to nonrecurring costs, despite improved EBITDA and cash position. The Q&A session highlighted concerns about market competition, regulatory challenges, and unclear future growth potential. The lack of a shareholder return plan and potential biosecurity business risks further weigh negatively. Despite some positive financial adjustments, the overall sentiment is negative, with potential risks outweighing the positives.